PLx Pharma Inc. Appoints Janet Barth to Newly Created Role of Vice President, Investor Relations & Corporate Communications
January 19 2022 - 5:50AM
PLx Pharma Inc. (NASDAQ: PLXP) (“PLx” or the “Company”), is a
commercial-stage drug delivery platform technology company focused
on its clinically-validated and patent-protected PLxGuard™ that has
the potential to improve the absorption of many drugs currently on
the market and to reduce the risk of stomach injury associated with
certain drugs. The Company, with its lead products VAZALORE™ 325 mg
and VAZALORE™ 81 mg liquid-filled aspirin capsules (referred to
together as “VAZALORE”), announced today the appointment of Janet
M. Barth as Vice President, Investor Relations & Corporate
Communications, effective immediately. As a member of the Executive
Leadership Team, Ms. Barth will report directly to Natasha
Giordano, PLx Pharma’s President & CEO.
Ms. Barth will be responsible for expanding the
Company’s proactive and strategic investor relations program to
increase shareholder value and broaden its reach within the
investment community.
Natasha Giordano, President & CEO, said, "We
are excited to welcome Janet to our leadership team. Her vast
experience in all facets of corporate, financial and investor
communications will be a tremendous asset for us as we continue to
build our business and strengthen relationships with important
stakeholders, including the financial community. Many of us on the
team have worked with Janet previously, and I am thrilled to join
forces with her again as she leads a best-in-class investor
relations program at PLx Pharma.”
Ms. Barth’s experience spans nearly 30 years of
broad-reaching, finance-driven investor relations and corporate
communications with publicly held pharmaceutical and retail
companies. Previously she served as Senior Vice President –
Investor Relations and Corporate Communications for Adams
Respiratory Therapeutics, a specialty pharmaceutical company
focused on OTC and prescription products for the treatment of
respiratory disorders, until its successful merger with Reckitt
Benckiser in 2008. She began her career at Schering-Plough
Corporation, a $20 billion global science-based healthcare company,
where she held positions of increasing responsibility in Corporate
Communications and Investor Relations during a tenure of almost 20
years, including as its Investor Relations Officer up until to its
2009 merger with Merck & Co. Most recently, Ms. Barth served 7
years as Vice President – Investor Relations at Bed Bath &
Beyond, a $9 billion North American omnichannel retailer focused on
the Home, Baby and Wellness markets. She earned a Bachelor of Arts
from Dickinson College and an MBA from Seton Hall University.
About VAZALORE VAZALORE is an
FDA-approved liquid-filled aspirin capsule, available in 81 mg and
325 mg doses. VAZALORE delivers aspirin differently from plain and
enteric coated aspirin products. The special complex inside the
capsule is designed for targeted release of aspirin, limiting its
direct contact with the stomach. VAZALORE delivers fast, reliable
absorption for pain relief plus the lifesaving benefits of aspirin.
To learn more about VAZALORE, please visit www.vazalore.com.
About PLx Pharma Inc.
PLx Pharma, Inc. is a commercial-stage drug
delivery platform technology company focused on improving how and
where active pharmaceutical ingredients (APIs) are absorbed in the
gastrointestinal (GI) tract via its clinically validated and patent
protected PLxGuard™ technology. PLx believes this platform has the
potential to improve the absorption of many drugs currently on the
market or in development, and to reduce the risk of stomach injury
associated with certain drugs. To learn more about PLx Pharma Inc.
and its pipeline, please visit www.plxpharma.com.
CONTACTS:
Janet M. Barth Vice President, Investor
Relations & Corporate Communications, PLx Pharma Inc.(973)
409-6542IR@PLxPharma.com
Lisa M. WilsonFounder & President, In-Site
Communications, Inc. (212) 452-2793lwilson@insitecony.com
Source: PLx Pharma Inc.
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jun 2024 to Jul 2024
PLx Pharma (NASDAQ:PLXP)
Historical Stock Chart
From Jul 2023 to Jul 2024